Sara Tolaney· @stolaney1 · X·· 2 天前评分90
正文 · 原文
TALENT trial presented by Sara Hurvitz: Preop TDXd in HR+ HER2-low breast cancer
Preop TDXd: 7%
TDXd+AI: 3%
TDXd-->TC: 9%
Adding endocrine therapy and sequencing chemo with TDXd didn't seem to improve pCR
@OncoAlert #ESMO2026
1008 浏览 · 21 赞 · 17 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Sara Tolaney · x.com